```html

Uterine Bleeding After Menopause

What is Uterine Bleeding After Menopause?

Post‑menopausal uterine bleeding (PMB) is any vaginal bleeding that occurs 12 months or more after a woman’s final menstrual period. By definition, a woman is considered post‑menopausal when she has not had a period for at least one year and her blood levels of estrogen and progesterone are low enough that the ovaries no longer produce eggs.

Because the endometrium (the lining of the uterus) normally thins after menopause, any bleeding is abnormal and warrants evaluation. While most cases are benign, some are a sign of serious disease such as endometrial cancer, which makes early detection essential.

Common Causes

The following are the most frequently encountered reasons for post‑menopausal bleeding. In many cases more than one factor may be present.

• Endometrial atrophy – thinning of the uterine lining due to low estrogen; the most common benign cause.
• Endometrial hyperplasia – thickening of the lining, often related to unopposed estrogen exposure (e.g., hormone therapy without progesterone).
• Endometrial (uterine) cancer – malignant growth of the uterus; accounts for ~10 % of PMB cases but is the most serious.
• Uterine polyps – benign growths that can protrude into the cervical canal and bleed.
• Hormone therapy (HT) – especially estrogen‑only therapy or an improperly balanced estrogen‑progestin regimen.
• Medications that affect clotting – anticoagulants (warfarin, direct oral anticoagulants), antiplatelet agents (aspirin, clopidogrel), and some herbal supplements.
• Pelvic organ prolapse – descent of the uterus or vaginal walls can cause irritation and bleeding.
• Uterine infections – rare but possible (e.g., endometritis, chlamydia, tuberculosis).
• Vaginal atrophy (atrophic vaginitis) – thinning of the vaginal epithelium due to estrogen deficiency, leading to fragile tissue that may bleed.
• Other gynecologic cancers – cervical, vaginal, or vulvar cancers can present with post‑menopausal bleeding.

Associated Symptoms

Women with PMB often notice other changes that can help clinicians narrow the cause:

• Spotting versus heavy flow (clots, soaking pads)
• Pain or cramping in the lower abdomen or pelvis
• Discharge that is foul‑smelling or mucous‑like
• Weight loss or loss of appetite (possible malignancy)
• Pelvic pressure or a sensation of fullness
• Signs of anemia (fatigue, shortness of breath, pale skin)
• Urinary symptoms (frequency, urgency) if a mass is pressing on the bladder

When to See a Doctor

Any vaginal bleeding after menopause should be reported promptly. Seek medical care right away if you notice:

• Bleeding that is heavy enough to change a pad or tampon in less than an hour.
• Bleeding that persists for more than two days.
• Accompanying symptoms such as severe pelvic pain, fever, or foul‑smelling discharge.
• Significant weight loss, night sweats, or a change in bowel/bladder habits.

Even a small amount of spotting warrants evaluation because it can be the first sign of endometrial cancer.

Diagnosis

Evaluation typically follows a stepwise approach:

1. Medical History & Physical Examination

• Review of menstrual and hormonal therapy history, medication list, and risk factors for cancer (obesity, diabetes, family history, early menarche, late menopause).
• Pelvic exam to assess the cervix, vagina, uterus, and adnexa for lesions, masses, or atrophy.

2. Laboratory Tests

• Complete blood count (CBC) – looks for anemia.
• Coagulation profile – if on anticoagulants.
• Serum β‑hCG – to rule out a rare persistent pregnancy.

3. Imaging

• Transvaginal ultrasound (TVUS) – first‑line; measures endometrial thickness. A thickness > 4 mm in a post‑menopausal woman typically triggers further evaluation (American College of Obstetricians and Gynecologists, ACOG).
• Saline infusion sonohysterography (SIS) – adds contrast to better visualize polyps or submucosal fibroids.
• Pelvic MRI or CT – reserved for suspicious masses or staging of known cancer.

4. Tissue Sampling

• Endometrial biopsy – office‑based sampling of the uterine lining; the gold standard for ruling out hyperplasia or cancer.
• Dilation & curettage (D&C) – performed when the office biopsy is inadequate or when more tissue is needed.
• Hysteroscopy – direct visual inspection with the ability to remove polyps or take targeted biopsies.

Treatment Options

Treatment is tailored to the underlying cause, severity of bleeding, and the patient’s overall health.

1. Medical Management

• Hormone therapy adjustment – adding progesterone to estrogen‑only regimens; switching to a lower estrogen dose.
• Progestin therapy – oral medroxyprogesterone acetate 10–20 mg daily for 14 days, or a levonorgestrel‑releasing intrauterine system (LNG‑IUS) for localized effect.
• Tranexamic acid – an antifibrinolytic that reduces bleeding if the cause is vascular (e.g., polyp).
• Aromatase inhibitors – used in individuals with estrogen‑dependent hyperplasia who cannot take progestins.
• Topical estrogen – for vaginal atrophy; improves mucosal integrity and may reduce spotting.

2. Surgical & Procedural Options

• Polypectomy – hysteroscopic removal of polyps; often curative.
• Hysteroscopic resection of hyperplasia – for focal lesions.
• Myomectomy – removal of submucosal fibroids causing bleeding.
• Hysterectomy – definitive treatment for refractory bleeding, cancer, or extensive disease.
• Endometrial ablation – minimally invasive destruction of the lining; not appropriate if cancer is suspected.

3. Supportive Care

• Iron supplementation for anemia (ferrous sulfate 325 mg PO daily).
• Dietary counseling to increase iron-rich foods.
• Follow‑up appointments to reassess bleeding and repeat imaging/biopsy as recommended.

Prevention Tips

While some causes (e.g., cancer) cannot be completely prevented, several strategies can reduce risk and lower the chance of bleeding:

• Maintain a healthy weight (BMI < 30). Obesity increases estrogen production in adipose tissue and raises cancer risk.
• Control diabetes and hypertension – both are independent risk factors for endometrial cancer.
• Use hormone therapy according to guidelines: combine estrogen with progestin if you have an intact uterus; limit duration to the lowest effective dose.
• Stay current with regular gynecologic exams and pelvic ultrasounds if you have known polyps, hyperplasia, or are on long‑term HT.
• Eat a balanced diet rich in fruits, vegetables, and fiber; some studies suggest a protective effect against endometrial cancer.
• Quit smoking – smoking is linked with several gynecologic malignancies.
• Limit alcohol intake to ≤ 1 drink per day.
• Report any new vaginal spotting promptly, even if it seems minor.

Emergency Warning Signs

References

• Mayo Clinic. “Postmenopausal bleeding.” Updated 2023. https://www.mayoclinic.org
• American College of Obstetricians and Gynecologists. “ACOG Practice Bulletin No. 194: Endometrial Hyperplasia.” 2022.
• National Cancer Institute. “Uterine (Endometrial) Cancer Treatment (PDQ®)–Health Professional Version.” Accessed 2024.
• Centers for Disease Control and Prevention. “Hormone Replacement Therapy.” 2023.
• Cleveland Clinic. “Postmenopausal Bleeding: Causes, Diagnosis, Treatment.” 2024.
• World Health Organization. “Guidelines for the Management of Gynecologic Cancers.” 2021.

```